INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

Ads

You May Also Like

Sanofi delivers 2018 business EPS growth of 5.1% at CER

Paris, February 7, 2019 Sanofi delivers 2018 business EPS growth of 5.1% at CER ...

ContraFect Corporation Prices $10 Million Public Offering of Common Stock

YONKERS, N.Y., July 27, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company ...

Inovio Pharmaceuticals to Present at Biotech Showcase

PLYMOUTH MEETING, Pa., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...